Tandem Mobi | Tandem Diabetes Care

Impressively Small

The Tandem Mobi system is so small that it can be worn almost anywhere, giving you greater discretion, comfort, and options for how you manage your diabetes.

Wear it on-body with a lightweight adhesive sleeve (sold separately)
Clip it discreetly to your clothes
Slip it into the coin pocket of your jeans (yes, it's that small!)

iPhone Control

Life calls, the Tandem Mobi system answers. It’s the small, automated insulin delivery system that's controllable with a compatible, personal iPhone,* offering next-level comfort, convenience, and discretion. This is innovative diabetes management.

Control-IQ Technology

Tandem Mobi is powered by Control-IQ — the same advanced hybrid closed-loop technology that makes the t:slim X2 insulin pump the #1 rated automated insulin delivery system.²

Additional Features

5-inch Tubing Option

Wireless Charging

200-Unit Cartridge

Remote Software Updates^†

Water-Resistant (IP28)^‡

LED Status Indicator

Tandem Choice Program

Get a t:slim X2 insulin pump between now and December 31, 2023, and you may be eligible to switch to the new Tandem Mobi system for a one-time payment of just $199 when it becomes available. Additional terms and conditions apply.

Get Details

When will Tandem Mobi be available?

A limited release of the Tandem Mobi system is expected to start in late 2023, with full commercial availability expected in 2024.

If you purchase a t:slim X2 insulin pump between July 1 and December 31, 2023, you can switch to the Tandem Mobi system for a one-time payment of just $199. Check out the Tandem Choice Program for more information.

First Name

Last Name

Email Address

Zip or Postal Code

Phone Number

Consent

Responsible Use of Control‑IQ Technology

Even with advanced systems such as Control-IQ technology, you are still responsible for actively managing your diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires your accurate input of information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless you use all system components, including your CGM, infusion sets and pump cartridges, as instructed. Importantly, the system cannot adjust your insulin dosing if the pump is not receiving CGM readings. Because there are situations and emergencies that the system may not be capable of identifying or addressing, always pay attention to your symptoms and treat according to your healthcare provider’s recommendations.

* The mobile app requires a compatible iPhone model and operating system (sold separately). Only available to pump users who reside in the United States. A complete list of compatible iPhones will be released closer to commercial availability.

† Future updates for all or some of Tandem’s products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.

‡ Tested at 8 feet for 2 hours (IP28 rating).

References

1. As of Sept., 2023. Data on file, Tandem Diabetes Care.

2. dQ&A US Patient Panel Q3 2023 (July-Sept. 2023).

Important Safety Information

RX ONLY.

Indications for Use

Tandem Mobi insulin pump with interoperable technology: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater.

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin.

Control-IQ technology: Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control IQ-technology is indicated for use with NovoLog or Humalog U-100 insulin.

Warning: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of a Tandem insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The Tandem pump, and the CGM transmitter (when applicable) and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

Tandem Mobi receives FDA clearance!

Impressively Small

iPhone Control

Control-IQ Technology

Additional Features

Tandem Choice Program

When will Tandem Mobi be available?

About Tandem

Disclosures

Tandem Mobi receives FDA clearance!

Impressively Small

iPhone Control

Control-IQ Technology

Additional Features

Tandem Choice Program

When will Tandem Mobi be available?

Sign up now and get the latest news on the Tandem Mobi system